Oculis (NASDAQ:OCS) Shares Gap Up – What’s Next?

Shares of Oculis Holding AG (NASDAQ:OCS) gapped up prior to trading on Monday . The stock had previously closed at $23.07, but opened at $24.33. Oculis shares last traded at $23.7550, with a volume of 42,265 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on OCS shares. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. JPMorgan Chase & Co. began coverage on shares of Oculis in a research report on Friday, December 19th. They set an “overweight” rating and a $38.00 price objective for the company. HC Wainwright boosted their target price on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of Oculis in a research report on Tuesday, November 11th. Finally, Chardan Capital reiterated a “buy” rating and set a $51.00 price target on shares of Oculis in a report on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $41.50.

Oculis Trading Down 0.2%

The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -9.14 and a beta of 0.31. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The business has a fifty day moving average price of $19.92 and a 200 day moving average price of $18.97.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. As a group, equities analysts forecast that Oculis Holding AG will post -2.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OCS. Compagnie Lombard Odier SCmA boosted its holdings in shares of Oculis by 11.5% during the second quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock valued at $1,883,000 after acquiring an additional 10,000 shares during the period. Geode Capital Management LLC lifted its stake in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after acquiring an additional 6,384 shares during the period. Marshall Wace LLP acquired a new position in shares of Oculis during the second quarter valued at approximately $393,000. Bosun Asset Management LLC bought a new stake in Oculis during the second quarter worth approximately $378,000. Finally, Bank of America Corp DE lifted its position in Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the period. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.